Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Takeda Pharmaceutical Co. (TAK) had Receiveable Turnover of 6.32 for the most recently reported fiscal year, ending 2025-03-31.
| Income Statement Financials | |
$30.24B |
|
$712.32M |
|
$10.43B |
|
$19.81B |
|
$27.98B |
|
$2.26B |
|
$-1.11B |
|
$1.16B |
|
$1.16B |
|
$713.74M |
|
$713.74M |
|
$713.74M |
|
$713.74M |
|
$2.26B |
|
$7.29B |
|
3.16B |
|
3.21B |
|
$0.23 |
|
$0.22 |
|
| Balance Sheet Financials | |
$16.64B |
|
$12.99B |
|
$77.40B |
|
$94.04B |
|
$16.54B |
|
$26.18B |
|
$31.72B |
|
$48.26B |
|
$45.78B |
|
$-13.33B |
|
$45.78B |
|
3.15B |
|
| Cash Flow Statement Financials | |
$6.98B |
|
$-2.42B |
|
$-4.96B |
|
$3.02B |
|
$2.54B |
|
$-479.73M |
|
$480.92M |
|
$-2.00B |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.01 |
|
-- |
|
-- |
|
0.36 |
|
0.65 |
|
65.51% |
|
7.48% |
|
7.48% |
|
24.10% |
|
3.82% |
|
2.36% |
|
$5.65B |
|
-- |
|
-- |
|
-- |
|
0.32 |
|
1.30 |
|
|
Receiveable Turnover |
6.32 |
57.78 |
|
1.56% |
|
-5.35% |
|
0.76% |
|
0.99% |
|
$14.54 |
|
$1.76 |
|
$2.17 |
|